{"title":"gammaCore设备用于治疗伴有情绪障碍的退伍军人的慢性创伤后头痛:一例报告。","authors":"Jason Parmar, Darlene Makulski","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic posttraumatic headache (CPTHA) is a prevalent condition following traumatic brain injury, especially among veterans, with a significant impact on quality of life. Traditional treatments often lack efficacy and evidence-based support.</p><p><strong>Case report: </strong>We report the case of a 46-year-old male veteran with CPTHA, nonresponsive to standard therapies, including botulinum toxin A and oral medications. The patient underwent treatment with the gammaCore vagus nerve stimulator, a US Food and Drug Administration-cleared device intended for migraine and cluster headache management.</p><p><strong>Conclusions: </strong>Following initiation of gammaCore therapy, the patient experienced a marked reduction in headache intensity and frequency, alongside significant improvements in anxiety levels. These outcomes suggest that gammaCore may be a promising noninvasive treatment option for CPTHA, particularly in patients with coexisting mood disorders. Further research is warranted to validate these findings and establish gammaCore's role in CPTHA management.</p>","PeriodicalId":520525,"journal":{"name":"Pain medicine case reports","volume":"9 2","pages":"119-122"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"gammaCore Device for Chronic Posttraumatic Headache Pain Management in Veterans With Comorbid Mood Disorders: A Case Report.\",\"authors\":\"Jason Parmar, Darlene Makulski\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic posttraumatic headache (CPTHA) is a prevalent condition following traumatic brain injury, especially among veterans, with a significant impact on quality of life. Traditional treatments often lack efficacy and evidence-based support.</p><p><strong>Case report: </strong>We report the case of a 46-year-old male veteran with CPTHA, nonresponsive to standard therapies, including botulinum toxin A and oral medications. The patient underwent treatment with the gammaCore vagus nerve stimulator, a US Food and Drug Administration-cleared device intended for migraine and cluster headache management.</p><p><strong>Conclusions: </strong>Following initiation of gammaCore therapy, the patient experienced a marked reduction in headache intensity and frequency, alongside significant improvements in anxiety levels. These outcomes suggest that gammaCore may be a promising noninvasive treatment option for CPTHA, particularly in patients with coexisting mood disorders. Further research is warranted to validate these findings and establish gammaCore's role in CPTHA management.</p>\",\"PeriodicalId\":520525,\"journal\":{\"name\":\"Pain medicine case reports\",\"volume\":\"9 2\",\"pages\":\"119-122\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pain medicine case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain medicine case reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
gammaCore Device for Chronic Posttraumatic Headache Pain Management in Veterans With Comorbid Mood Disorders: A Case Report.
Background: Chronic posttraumatic headache (CPTHA) is a prevalent condition following traumatic brain injury, especially among veterans, with a significant impact on quality of life. Traditional treatments often lack efficacy and evidence-based support.
Case report: We report the case of a 46-year-old male veteran with CPTHA, nonresponsive to standard therapies, including botulinum toxin A and oral medications. The patient underwent treatment with the gammaCore vagus nerve stimulator, a US Food and Drug Administration-cleared device intended for migraine and cluster headache management.
Conclusions: Following initiation of gammaCore therapy, the patient experienced a marked reduction in headache intensity and frequency, alongside significant improvements in anxiety levels. These outcomes suggest that gammaCore may be a promising noninvasive treatment option for CPTHA, particularly in patients with coexisting mood disorders. Further research is warranted to validate these findings and establish gammaCore's role in CPTHA management.